Urinary metabolites of valproic acid in epileptic patients. 1998

H Katayama, and M Watanabe, and H Yoshitomi, and H Yoshida, and H Kimoto, and A Kamiya, and T Hayashi, and T Akimura
Fukuyama University, Faculty of Pharmacy and Pharmaceutical Sciences, Hiroshima, Japan.

The urinary excretion of valproic acid (VPA) and its metabolites (3-keto VPA, 3-OH VPA, and VPA-glucuronide) in 6 epileptic patients was studied using gas chromatography-mass spectrometry. The amount of VPA and 3-OH VPA excreted in the urine was low (0.1-0.5% of the dose of VPA and 0.6-1.5% of the dose of 3-OH administered). The amount of 3-keto VPA and glucuronide (VPA-Glu) excreted was marked (5.8-26.2% and 13.1-88.7% of the dose of VPA administered, respectively). The urinary excretion of VPA and its metabolites by patients who have taken a normal amount of a VPA preparation was almost the same as that of healthy volunteers. Two epileptic patients who took a large amount of the VPA preparation showed a high excretion of VPA-Glu without an increase in their plasma VPA-Glu.

UI MeSH Term Description Entries
D008297 Male Males
D008401 Gas Chromatography-Mass Spectrometry A microanalytical technique combining mass spectrometry and gas chromatography for the qualitative as well as quantitative determinations of compounds. Chromatography, Gas-Liquid-Mass Spectrometry,Chromatography, Gas-Mass Spectrometry,GCMS,Spectrometry, Mass-Gas Chromatography,Spectrum Analysis, Mass-Gas Chromatography,Gas-Liquid Chromatography-Mass Spectrometry,Mass Spectrometry-Gas Chromatography,Chromatography, Gas Liquid Mass Spectrometry,Chromatography, Gas Mass Spectrometry,Chromatography, Mass Spectrometry-Gas,Chromatography-Mass Spectrometry, Gas,Chromatography-Mass Spectrometry, Gas-Liquid,Gas Chromatography Mass Spectrometry,Gas Liquid Chromatography Mass Spectrometry,Mass Spectrometry Gas Chromatography,Spectrometries, Mass-Gas Chromatography,Spectrometry, Gas Chromatography-Mass,Spectrometry, Gas-Liquid Chromatography-Mass,Spectrometry, Mass Gas Chromatography,Spectrometry-Gas Chromatography, Mass,Spectrum Analysis, Mass Gas Chromatography
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic

Related Publications

H Katayama, and M Watanabe, and H Yoshitomi, and H Yoshida, and H Kimoto, and A Kamiya, and T Hayashi, and T Akimura
January 2003, Drug metabolism and disposition: the biological fate of chemicals,
H Katayama, and M Watanabe, and H Yoshitomi, and H Yoshida, and H Kimoto, and A Kamiya, and T Hayashi, and T Akimura
April 1981, Epilepsia,
H Katayama, and M Watanabe, and H Yoshitomi, and H Yoshida, and H Kimoto, and A Kamiya, and T Hayashi, and T Akimura
September 1987, The Japanese journal of psychiatry and neurology,
H Katayama, and M Watanabe, and H Yoshitomi, and H Yoshida, and H Kimoto, and A Kamiya, and T Hayashi, and T Akimura
January 2001, Chronobiology international,
H Katayama, and M Watanabe, and H Yoshitomi, and H Yoshida, and H Kimoto, and A Kamiya, and T Hayashi, and T Akimura
September 1978, Clinical pharmacology and therapeutics,
H Katayama, and M Watanabe, and H Yoshitomi, and H Yoshida, and H Kimoto, and A Kamiya, and T Hayashi, and T Akimura
April 2007, International journal of pediatric otorhinolaryngology,
H Katayama, and M Watanabe, and H Yoshitomi, and H Yoshida, and H Kimoto, and A Kamiya, and T Hayashi, and T Akimura
May 2018, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP,
H Katayama, and M Watanabe, and H Yoshitomi, and H Yoshida, and H Kimoto, and A Kamiya, and T Hayashi, and T Akimura
May 2004, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences,
H Katayama, and M Watanabe, and H Yoshitomi, and H Yoshida, and H Kimoto, and A Kamiya, and T Hayashi, and T Akimura
January 2004, Revista de neurologia,
H Katayama, and M Watanabe, and H Yoshitomi, and H Yoshida, and H Kimoto, and A Kamiya, and T Hayashi, and T Akimura
February 1996, Therapeutic drug monitoring,
Copied contents to your clipboard!